(UroToday.com) In this study, Dr. Karim Fizazi discussed the health-related quality of life (HRQoL) data from the VISION study of 177Lu-PSMA-617 (Lu-PSMA). While the results of the VISION study, published earlier this year, demonstrated a significant improvement in radiographic progression-free survival (rPFS) and overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC), this is the first report of the HRQoL data.1